AnaptysBio (ANAB) Q2 Revenue Jumps 103%

AnaptysBio (ANAB) reported strong Q2 2025 results, with GAAP revenue more than doubling year-over-year to $22.3 million, significantly exceeding analyst estimates, and GAAP EPS improving to $(1.34). This performance was primarily driven by increased royalty income from GSK's Jemperli, which is nearing a $1 billion annual sales milestone, and progress in its clinical pipeline, including positive Phase 2b data for rosnilimab. Despite these gains, the company continues to report net losses and decreasing cash reserves, highlighting its ongoing reliance on successful partner commercialization and critical upcoming clinical trial readouts for future financial stability.

Analysis

AnaptysBio (ANAB) reported a significant top-line beat for Q2 2025, with GAAP revenue of $22.3 million more than doubling the prior year's $11.0 million and substantially exceeding the consensus estimate of $11.68 million. This outperformance was driven by a material increase in collaboration revenue, specifically from higher-than-expected royalties from GSK's Jemperli, which saw its own sales grow over 19% quarter-over-quarter to $262 million. The company's bottom line also showed improvement, with a GAAP net loss per share narrowing to $(1.34) from $(1.71) in the prior-year period, beating estimates of a $(1.55) loss. Operationally, the company is advancing its key asset, rosnilimab, which completed a successful Phase 2b study in rheumatoid arthritis, with a pivotal data readout from a Phase 2 trial in ulcerative colitis expected in Q4 2025. Despite these positives, AnaptysBio remains unprofitable and its cash reserves of $293.7 million are decreasing, though management asserts this provides a cash runway through the end of 2027. The company's financial model is heavily dependent on near-term catalysts from its partners, including a potential $75 million milestone from GSK upon Jemperli reaching $1 billion in annual sales and up to $35 million in milestones from Vanda following its planned BLA submission for imsidolimab in the second half of 2025.

Key Decisions for Investors

• Given the strong revenue beat and accelerating royalty stream from GSK's Jemperli, investors should view the current results as a de-risking event for the company's revenue model, though continued net losses warrant attention.
• The most critical near-term catalyst is the topline Phase 2 data for rosnilimab in ulcerative colitis expected in Q4 2025; the outcome will be a primary determinant of the stock's future trajectory.
• Monitor partner-related news closely, specifically GSK's Jemperli sales figures to time the potential $75 million milestone payment and FDA communications regarding Vanda's imsidolimab BLA submission.
• While the company's guided cash runway to the end of 2027 provides a buffer, investors should scrutinize quarterly cash burn against the realization of royalty and milestone payments to validate the long-term financial stability.